LifeStance Health Group, Inc. (LFST) Free cash flow
- Free cash flow · 12 months (USD): Value $173.91M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value 10.97%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $173.91M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $217.87M − $43.96M ≈ $173.91M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | 10.97% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $173.91M ÷ $1.58B × 100 ≈ 10.97% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $217.87M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 4.31× | Operating cash flow / net income. Period ending 2026-06-30. $217.87M ÷ $50.60M ≈ 4.31× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | 217.87M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 43.96M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | 173.91M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 1.58B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | 50.60M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $173.91M | (m) | $217.87M | $43.96M | (m) | $1.58B | (m) | $50.60M | (m) | (m) | 10.97% | 4.31× |
| 2026-03-31 | $142.63M | (m) | $182.35M | $39.72M | (m) | $1.49B | (m) | $23.20M | (m) | (m) | 9.54% | 7.86× |
| 2025-12-31 | $110.03M | (m) | $146.15M | $36.13M | (m) | $1.42B | (m) | $9.66M | (m) | (m) | 7.72% | 15.12× |
| 2025-09-30 | $119.39M | (m) | $150.91M | $31.52M | (m) | $1.37B | (m) | $-9.12M | (m) | (m) | 8.73% | -16.55× |
| 2025-06-30 | $120.07M | (m) | $146.34M | $26.27M | (m) | $1.32B | (m) | $-16.15M | (m) | (m) | 9.12% | -9.06× |
| 2025-03-31 | $102.38M | (m) | $126.01M | $23.63M | (m) | $1.28B | (m) | $-35.64M | (m) | (m) | 7.98% | -3.54× |
| 2024-12-31 | $85.69M | (m) | $107.26M | $21.57M | (m) | $1.25B | (m) | $-57.44M | (m) | (m) | 6.85% | -1.87× |
| 2024-09-30 | $35.06M | (m) | $61.74M | $26.68M | (m) | $1.21B | (m) | $-95.29M | (m) | (m) | 2.91% | -0.65× |
| 2024-06-30 | $-17.76M | (m) | $13.66M | $31.42M | (m) | $1.16B | (m) | $-150.92M | (m) | (m) | -1.54% | -0.09× |
| 2024-03-31 | $-68.73M | (m) | $-30.83M | $37.90M | (m) | $1.10B | (m) | $-173.12M | (m) | (m) | -6.23% | 0.18× |
| 2023-12-31 | $-57.40M | (m) | $-16.88M | $40.52M | (m) | $1.06B | (m) | $-186.26M | (m) | (m) | -5.44% | 0.09× |
| 2023-09-30 | $-37.25M | (m) | $2.24M | $39.49M | (m) | $1.00B | (m) | $-187.96M | (m) | (m) | -3.71% | -0.01× |
| 2023-06-30 | $-11.47M | (m) | $33.32M | $44.79M | (m) | $959.09M | (m) | $-164.23M | (m) | (m) | -1.20% | -0.20× |
| 2023-03-31 | $-17.48M | (m) | $41.59M | $59.07M | (m) | $909.04M | (m) | $-187.48M | (m) | (m) | -1.92% | -0.22× |
| 2022-12-31 | $-26.47M | (m) | $52.79M | $79.25M | (m) | $859.54M | (m) | $-215.56M | (m) | (m) | -3.08% | -0.24× |
| 2022-09-30 | $-60.04M | (m) | $47.51M | $107.55M | (m) | $630.18M | (m) | $-276.94M | (m) | (m) | -9.53% | -0.17× |
| 2022-06-30 | $-88.90M | (m) | $27.57M | $116.46M | (m) | $412.62M | (m) | $-359.54M | (m) | (m) | -21.54% | -0.08× |
| 2022-03-31 | $-108.50M | (m) | $2.82M | $111.32M | (m) | $61.41M | (m) | $-360.84M | (m) | (m) | -176.69% | -0.01× |
| 2021-12-31 | $-85.07M | (m) | $9.42M | $94.49M | (m) | $1.45M | (m) | $-307.20M | (m) | (m) | -5887.34% | -0.03× |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $-48.40M | (m) | $-12.06M | $36.34M | (m) | $143.27M | (m) | $-21.81M | (m) | (m) | -33.78% | 0.55× |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-05-14 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $2.73M | (m) | $17.05M | $14.31M | (m) | $212.52M | (m) | $5.67M | (m) | (m) | 1.29% | 3.01× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeneDx Holdings Corp. (WGS) | United States | $2.638B | -19.23 |
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B |